



OPEN ACCESS

EDITED AND REVIEWED BY
Pascal Lapierre,
University of Montreal Hospital Centre
(CRCHUM), Canada

*CORRESPONDENCE
Lorenz Kocheise
✉ l.kocheise@uke.de

†These authors have contributed
equally to this work and share
last authorship

RECEIVED 12 January 2024
ACCEPTED 15 January 2024
PUBLISHED 24 January 2024

CITATION
Kocheise L, Piseddu I, Vonderlin J, Tjwa ET,
Buescher G, Meunier L, Goeggelmann P,
Fianchi F, Dumortier J, Barciela MR,
Gevers TJJ, Beretta-Piccoli BT,
Londoño M-C, Frankova S, Roesner T,
Joerg V, Schmidt C, Glaser F, Sutter JP,
Fründt TW, Lohse AW, Huber S, von Felden J,
Sebode M and Schulze K (2024)
Corrigendum: PD-1/PD-L1 immune
checkpoint therapy demonstrates favorable
safety profile in patients with autoimmune
and cholestatic liver disease.
Front. Immunol. 15:1369747.
doi: 10.3389/fimmu.2024.1369747

COPYRIGHT
© 2024 Kocheise, Piseddu, Vonderlin, Tjwa,
Buescher, Meunier, Goeggelmann, Fianchi,
Dumortier, Barciela, Gevers, Beretta-Piccoli,
Londoño, Frankova, Roesner, Joerg, Schmidt,
Glaser, Sutter, Fründt, Lohse, Huber, von
Felden, Sebode and Schulze. This is an open-
access article distributed under the terms of
the [Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

Lorenz Kocheise^{1,2*}, Ignazio Piseddu^{2,3}, Joscha Vonderlin^{2,4},
Eric T. Tjwa^{2,5}, Gustav Buescher^{1,2}, Lucy Meunier^{2,6},
Pia Goeggelmann⁷, Francesca Fianchi^{2,8}, Jérôme Dumortier^{2,9},
Mar Riveiro Barciela^{2,10}, Tom J. G. Gevers^{2,11,12},
Benedetta Terziroli Beretta-Piccoli^{2,13,14,15},
Maria-Carlota Londoño^{2,16}, Sona Frankova^{2,17}, Thomas Roesner¹⁸,
Vincent Joerg^{1,2}, Constantin Schmidt^{1,2}, Fabian Glaser^{1,2},
Jan P. Sutter^{1,2}, Thorben W. Fründt^{1,2}, Ansgar W. Lohse^{1,2},
Samuel Huber^{1,2}, Johann von Felden^{1,2}, Marcial Sebode^{1,2†}
and Kornelius Schulze^{1,2†}

¹Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany,

²European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany,

³Department of Medicine II, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany, ⁴Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁵Department of Gastroenterology and Hepatology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands, ⁶Service Hépatogastro-entérologie, Hôpital St-Eloi, CHU Montpellier, Montpellier, France, ⁷Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, ⁸CEMAD-Centro Malattie dell'Apparato Digerente, Fondazione Policlinico Universitario Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy, ⁹Service d'hépatogastro-entérologie, Hôpital Edouard Herriot – Hospices civils de Lyon, Université de Lyon, Lyon, France,

¹⁰Liver Unit, Department of Internal Medicine, Hospital Universitari Valle d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, ¹¹Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, Netherlands, ¹²Nutrim School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands, ¹³Epatocentro Ticino, Lugano, Switzerland,

¹⁴Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland, ¹⁵MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, United Kingdom, ¹⁶Liver Unit, Hospital Clinic Barcelona, FCRB-IDIBAPS, CIBEREHD, University of Barcelona, Barcelona, Spain, ¹⁷Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czechia, ¹⁸Department of Medical Oncology, National Center of Tumor Diseases (NCT) Heidelberg and Universitätsklinikum Heidelberg, Heidelberg, Germany

KEYWORDS

autoimmune disease (AID), immune checkpoint inhibitors (ICI), autoimmune liver diseases (AILD), immune related adverse effects (irAEs), PD-1/PD-L1 immune checkpoint inhibitors, autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC)

A corrigendum on

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

by Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Riveiro Barciela M, Gevers TJG, Terzioli Beretta-Piccoli B, Londoño M-C, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M and Schulze K (2024) *Front. Immunol.* 14:1326078. doi: 10.3389/fimmu.2023.1326078

In the published article, there was an error in **Table 2**. The count of monoclonal antibodies used was interchanged during production between the different antibodies. The corrected **Table 2** and its caption appear below.

The authors apologize for this error introduced during production and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 2 Immune-related adverse events and immunosuppression.

Baseline characteristics	Patients, n = 22 (%)
irAE	
Grade 1	3 (13.6)
Grade 2	5 (22.7)
None	14 (63.6)
Liver irAE	
Grade 1	2 (9.1)
Grade 2	1 (4.5)
Non-Liver irAE	
Colitis	1 (4.5)
Pneumonitis	1 (4.5)
Inflammatory arthritis	1 (4.5)
Rash	2 (9.1)
Treatment regimen before ICI[#]	
Mycophenolate mofetil	1 (4.5)
Azathioprine	4 (18.1)
Corticosteroids	2 (9.1)
Methotrexate*	1 (4.5)
UDCA	9 (40.9)
Obeticholic acid	1 (4.5)

(Continued)

TABLE 2 Continued

Baseline characteristics	Patients, n = 22 (%)
No treatment for AILD	7 (31.8)
Treatment adjustment during ICI therapy due to non-liver related events[#]	
Start Hydroxychloroquine*	1 (4.5)
Start or increase of corticosteroids	2 (9.1)
No change in treatment	16 (72.7)
Treatment adjustment during ICI therapy due to ILICI or AILD[#]	
Start or increase of corticosteroids	2 (9.1)
Start UDCA	1 (4.5)
Change from obeticholic acid to Fenofibrate	1 (4.5)
Stop Azathioprine	1 (4.5)
No change in treatment	16 (72.7)
Monoclonal antibody used	
Atezolizumab	7 (31.8)
Durvalumab	5 (22.7)
Pembrolizumab	4 (18.1)
Nivolumab	4 (18.1)
Nivolumab + Ipilimumab	1 (4.5)
Spartalizumab	1 (4.5)

No changes in immunosuppressive therapy were made before commencing ICI treatment to prevent potential irAEs. [#]Multiple treatments possible *Treatment for Rheumatoid arthritis.